205587-34-4

Upstream product

• 75-52-5 nitromethane 
• 99815-16-4 3,4-bis(tert-butyldimethylsilanyloxy)benzaldehyde 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 125251-66-3 Arbutamine hydrochloride 
• 205587-48-0 N-{(R)-2-[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-hydroxy-ethyl}-4-(4-methoxymethoxy-phenyl)-butyramide 
• 205587-49-1 (R)-1-[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-[4-(4-methoxymethoxy-phenyl)-butylamino]-ethanol 
• 459867-17-5 N-{2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-hydroxy-ethyl}-4-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-butyramide 
• 459867-18-6 1-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-{4-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-butylamino}-ethanol 
• 130783-37-8 Arbutamine 

Relevant academic research and scientific papers

Effect of ligand structure on the zinc-catalyzed Henry reaction. Asymmetric syntheses of (-)-denopamine and (-)-arbutamine

(Matrix presented) Syntheses of variously modified ligands for the dinuclear zinc catalysts for the asymmetric aldol and nitroaldol (Henry) reactions are reported. Catalytic enantioselective nitroaldol reactions promoted by these modified ligands led to efficient syntheses of the β-preceptor agonists (-)-denopamine and (-)-arbutamine.

Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof

Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1) 1and the process for producing thereof, and 1-substituted phenyl-2-amino alcohol derivatives having the formula (2) 2and the process for producing thereof from the

Catalytic asymmetric synthesis of arbutamine

An efficient catalytic asymmetric synthesis of (R)-arbutamine has been achieved using a catalytic asymmetric nitroaldol reaction promoted by a heterobimetallic multifunctional asymmetric catalyst as a key step.